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The mouse monoclonal ntibody ME 101 raised against human peripherin, an intermediate filament protein (IFP) spe- 
cific to well defined neuronal populations, recognizes allthe major classes of vertebrate IFP in immunoblotting assays. 
Desmin, GFAP, vimentin, peripherin and the lightest neurofilament protein (NF-L) were cleaved into carboxy- and 
amino-terminal h lves by N-chlorosuccinimide at their unique trytophan residue. Whereas the antibody directed against 
the epitope common to every IFP (intermediate filament antigen or IFA) and located on the carboxy-terminal end of 
the rod domain recognizes the carboxy-terminal h lf, the ME 101 antibody, as the present s udy illustrates, recognizes 
specifically the amino-terminal h lf. From the amino acid sequence data of IFP, it is deduced that he cognate epitope 
is localized on the amino-terminal p rt of coil la. 
Intermediate filament protein; Monoclonal ntibody; Immunoblotting; Consensus sequence; Peripherin; Neurofilament 
1. INTRODUCTION 
Protein and cDNA sequence data [1-11] show 
that one of the main characteristics of all in- 
termediate filament proteins (IFP), besides having 
two consensus equences located in the amino- 
terminal part of coil l a and at the carboxy- 
terminal end of coil 2 (IFA) [1,12], is the presence 
of a central a-helical rod domain which is well con- 
served in length and sequence features. In the 
carboxy-terminal end of coil 2, it has been shown 
that the common epitope is recognized by a murine 
monoclonal antibody elicited by Pruss et al. [13] 
against human glial fibrillary acidic protein 
(GFAP) and which allows the recognition of IFP 
in total protein preparations. It has been shown 
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that this antibody is not class-specific and that it 
can be used to identify most IFP in both vertebrate 
and invertebrate tissues, thus demonstrating that 
there is some conservation of the rod domain in the 
phylogeny [13,14]. Moreover, recent data indicate 
that this IFA antibody also recognizes the three 
nuclear lamins [15], i.e. the components of the 
nuclear lamina, underlying the inner nuclear mem- 
brane, which have been demonstrated to possess 
all the major structural features of IFP [16-18]. 
In contrast, the existence of an antibody reacting 
with the amino-terminal consensus equence of 
IFP has so far not been reported. 
Here, we describe a mouse monoclonal antibody 
raised against human peripherin, an intermediate 
filament protein specific to well defined neuronal 
populations [19,20], and then show that this an- 
tibody recognizes the amino-terminal half of all 
the major classes of vertebrate IFP in immunoblot- 
ting assays. 
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2. MATERIALS AND METHODS 
2.1. Preparation of peripherin for immunization 
Human sympathetic ganglia, obtained through sympathec- 
tomies, were frozen in liquid nitrogen immediately after exci- 
sion. Homogenates, prepared as already described [19], were 
immediately treated for electrofocusing. Proteins were 
separated by two-dimensional gel electrophoresis [21] and stain- 
ed with Coomassie blue. The spot corresponding to peripherin 
was cut out from 50 gels; in order to remove the stain and to 
concentrate he protein, the excised spots were all loaded on a 
12.5% polyacrylamide slab gel; after electrophoresis, 2 cm- 
wide strips were cut out from lateral edges of the gels, stained 
for 15 min with Coomassie blue and aligned back into position 
on the unstained gel; this permitted the localization of the 
peripherin band on the unstained portion of the gel. The band 
was excised, washed with phosphate buffered saline (PBS) for 
2 h by changing buffer four times, homogenized in a glass- 
Teflon Potter homogenizer. Sterile PBS was then added until 
the slurry was fluid enough to be pumped through a syringe. 
2.2. Immunization and production of hybridomas 
Balb/c mice were immunized by injecting into the foot pads 
the gel-slurry emulsified with an equal volume of complete 
Freund's adjuvant for the first shot, and with incomplete 
Freund's adjuvant for the subsequent shots on days 7, 14 and 
24. Three days after the last injection, spleen cells were isolated 
and used for somatic ell hybridization with the myeloma cell 
line P3 x 63 Ag 865.3 [22] according to the slightly modified 
[24-26] method of Kohler and Milstein [23]. Hybridomas were 
distributed in 96 microwell culture plates and grown in HAT 
medium (RPMI containing 15o70 fetal calf serum, 1070 sodium 
pyruvate, 1070 essential amino acids, 1 070 penistreptoglutamine). 
2.3. Selection of hybridomas 
Supernatants from wells containing proliferating hybridomas 
were assayed by immunoblotting. Total cellular extracts from 
human sympathetic ganglia were loaded on whole width of 
single 12.5070 polyacrylamide slab gels, electrophoresed for 
4-5 h and the proteins were then transferred to a nitrocellulose 
membrane in a Transfor apparatus; after saturation with 3070 
bovine serum albumin and washes as described by Towbin et al. 
[27], the membrane was cut to the right size and positioned in 
a 28-lane miniblotter apparatus (Immunetics, Cambridge, MA, 
USA). Each supernatant was introduced into a single lane. Us- 
ing two such devices, 50 supernatants could be tested each day 
and the remaining lanes being used for the controls. We chose 
as a standard, the IFA antibody elicited by Pruss et al. [13]. The 
supernatants which reacted with proteins migrating at positions 
between 50 and 60 kDa were then cross-checked with the pro- 
teins separated on two-dimensional polyacrylamide gels and 
transferred onto nitrocellulose membranes. Hybridomas reac- 
ting either with peripherin or with every IFP were selected. 
Supernatants from the subclones were tested identically. 
Selected hybridomas were expanded and obtained in the form 
of ascites after intraperitoneal injection into Swiss nude mice. 
The immunoglobulin subclass of the antibody was determin- 
ed by Mancini double immunodiffusion analysis using rabbit 
anti-mouse immunoglobulin quantitative immunodiffusion 
plates (Meloy Laboratories Inc., Springfield, 
2.4. Cell and tissue extracts 
Lysates from the mouse neuroblastoma NIE 115 cell line, and 
homogenates of human brain and sympathetic ganglia, of 
mouse and rabbit spinal cord and sciatic nerve, and of chicken 
gizzard and sciatic nerve were prepared as already described 
[19]; they were then treated for isoelectric focusing (IEF) [21] 
and stored at - 30°C. Cytokeratins from oral epithelia were ex- 
tracted as described by Franke et al. [28] and treated for non- 
equilibrium pH gradient electrophoresis (NEPHGE) [29]; they 
were numbered according to Moll et al. [30]. 
2.5. SDS-polyacrylamide g l electrophoresis 
Proteins were separated on two-dimensional polyacrylamide 
gels [21] and-were either transferred immediately onto 
nitrocellulose membranes or stained with Coomassie blue and 
excised for peptide analyses. All these methods have already 
been described [19]. 
2.6. N-Chlorosuccinimide treatment 
Protein spots cut out from two-dimensional gels were treated 
with N-chlorosuccinimide as described [31]. Peptides were 
resolved and analyzed on 15°70 slab gels containing 0.1070 SDS. 
2.7. Immunoblotting 
Proteins separated by polyacrylamide gel electrophoresis 
were transferred onto nitrocellulose membranes [27] in a 
Transfor apparatus at 500 mA for the 807o acrylamide two- 
dimensional gels and at 700 mA for the 15070 acrylamide slab 
gels; in both cases the transfer time was 1 h. Proteins and pep- 
tides were visualized on the membranes by staining with 
Ponceau red as described [19], and their positions were marked 
as points with a pencil. 
lmmunostaining was as described by Dellagi et al. [32]. The 
hybridoma scites fluid was used at a dilution of 1 : 100. The 
murine IFA hybridoma clone was a gift from Dr B.H. Ander- 
ton (St. George's Hospital, London); it was used as a 
hybridoma supernatant diluted 1 : 1. 
3. RESULTS 
3.1. Selection o f  hybr idomas 
First ly ,  hybr idomas  were selected on  min ib lo ts  
onto  wh ich  prote ins  f rom to ta l  ext racts  o f  e i ther  
human sympathet ic  gang l ia  or  mouse  N IE  115 
neurob las toma cells had  been t rans fer red  a f ter  
separat ion  on  s lab gels (not  shown) .  Th is  enab led  
one  to  check  a number  o f  hybr idomas  
s imul taneous ly  under  ident ica l  cond i t ions  and  
aga ins t  to ta l  cell ext racts  conta in ing  not  on ly  the 
prote in  under  s tudy  but  a lso many other  s imi lar  
p ro te ins .  For  example ,  a to ta l  ext ract  f rom human 
sympathet ic  gang l ia  conta ins  several  I FP  ( the 
t r ip le t  o f  neuro f i lament  prote ins ,  v iment in  and  
per ipher in ) ,  whereas  that  f rom mouse  
neurob las toma conta ins  the  co -expressed  v iment in  
and  per ipher in .  Desp i te  the fact  that  the  xno lecu lar  
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masses o f  the latter two proteins are almost iden- 
tical, they are only clearly separated on two- 
d imensional  gels. This is why the hybr idomas were 
first selected on rniniblots and then checked 
against  to ta l  cell or  tissue proteins separated on 
two-d imensional  gels. 
The results obtained with hybr idoma ME 101, 
whose ant ibody belongs to the lgM class are shown 
in fig.1. Clearly,  it reacts with the l ightest 
neurof i lament protein (NF-L),  v imentin and its 
derived peptides [33], the dif ferent isoforms of  
per ipher in [34], GFAP,  desmin and every 
cytokerat in  present in the preparat ion f rom human 
oral  epithelia. These data  init ial ly led us to 
postulate that ME 101 behaves like the previously 
descr ibed IFA  ant ibody elicited by Pruss el al. 
[13]. This reagent recognizes the consensus se- 
quence common to every IFP  which is located at 
the carboxy-terminal  end of  the rod domain.  
However,  the subsequent experiments clearly 
Fig.I. Immunoreaetivity of intermediate filament proteins to ME 101. (A) Portion of a Coomassie blue stained two-dimensional gel 
(8% acrylamide-0.09% bisacrylamide) loaded with an extract from human sympathetic ganglia. (B} Western blot of A and 
immunodetection with ME 101. (C) As in A but the extract was from mouse neuroblastoma NIE 115 cell line. (D) Western blot of 
C and as in B. (E) As in A and C but the extract was from chicken gizzard. {F) Western blot of E and as in B. (G) As in A, C and 
E but extract was from human mesencephalon. (H) Western blot of G and as in B. ([) Portion of a Ponceau red stained blot. l'he 
first-dimensional gel (NEPHGE) had been loaded with a preparation of cytokeratins from human oral epithelia. The concentration 
of acrylamide in the second-dimensional gel was 10% with 0.27% bisaerylamide. (J} lmmunodetection f ] and as in B. Pe 61, Pe 
58, Pe 56, isoforms of peripherin; Vi, vimentin; riDs, vimentin-derived proteins; NF-L, the lightest neurofilament protein; NF-L Ds, 
NF-L-derived proteins; GFAP. glial fibrillary acidic protein; GFAP Ds, GFAP-derived proteins; De, desmin; 1,2,5 .... cytokeratins; 
arrows, complexes formed between type I and type II keratins; at, az./~, tubulin subunits; Ac, actin; PGK, phosphoglueokinase; BSA, 
bovine serum albumin. These three last proteins were added as markers in I. 
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established that our monoclonal ntibody displays 
a different specificity. It is remarkable that the in- 
tensity of the reaction differs according to the IFP 
and the antibody used. This is particularly evident 
when the cell extract loaded onto the gel contains 
several different IFP. For instance, in extracts 
from human sympathetic ganglia, peripherin is 
first decorated to a very large extent by the IFA an- 
tibody, then vimentin and lastly, NF-L. In con- 
trast, using ME 101, NF-L is first decorated very 
intensely, followed by vimentin and peripherin. In 
extracts from human brain, NF-L was also 
decorated very strongly by the ME 101 antibody 
but only weakly by the IFA antibody. No signifi- 
cant reaction could be detected with the two 
heaviest NFP subunits on two-dimensional 
polyacrylamide g ls, using either antibody; a reac- 
tion was, however, observed with the IFA an- 
tibody when purified NFP were separated on slab 
gels [14]. One may ask whether the largest NF 
subunits undergo complete denaturation during 
two-dimensional gel electrophoresis in view of the 
fact that the first dimension gels are only 
equilibrated in a SDS-containing buffer whereas in 
the case of slab gels the protein samples are boiled 
with SDS. 
3.2. Recognition of the carboxy-termina/ moiety 
of IFP 
Geisler et al. [35] have demonstrated that 
desmin, NF-L, vimentin and GFAP contain a uni- 
que tryptophan residue sited in the central part of 
the rod domain. We have demonstrated that 
peripherin also displays asingle tryptophan residue 
at this same location [19]. Combination of the N- 
chlorosuccinimide treatment, which cuts the 
molecules pecifically at their tryptophan residue, 
with immuno.staining of the peptides, transferred 
onto a nitrocellulose membrane after separation 
on a slab gel, using the IFA antibody allows one to 
localize the carboxy-terminal moiety of IFP as 
shown in fig.2. This reactivity is found to reside in 
the lightest peptide for peripherin, vimentin and 
GFAP, and in the heaviest one for NF-L; this is in 
agreement with available data concerning their 
respective molecular masses which have been 
shown to depend mostly on the length of the 
carboxy-terminal t il domain [12]. 
3.3. Localization of the common epitope 
recognized by ME 101 
The same experiment was repeated applied to 
ME 101 with IFP from several origins (human 
B 
NT T 
Fig.2. Determination of the carboxy-terminal moiety of some intermediate filament proteins. (A) Coomassie blue staining of the 
peptides cleaved from intermediate filament proteins with N-chlorosuccinimide. P ptides were separated on gels containing 15% 
acrylamide and 0.2% bisacrylamide. (B) Immunodetection of the carboxy-terminal moiety by decoration with the IFA antibody. The 
gels shown in A were blotted partly before Coomassie blue staining so that Coomassie blue and Ponceau red stainings coincided 
perfectly. After Ponceau red staining, the bands were marked on the blot as points with a pencil. Immunodetection of the carboxy- 
terminal moiety was carried out with the IFA antibody. T, N-chlorosuccinimide tr ated protein; NT, non-treated protein. Other 
abbreviations are as in fig.1. 
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Fig.3. Immunodetection f the amino-terminal moiety with ME 101. Peptides were prepared, separated and blotted as in fig.2. 
Immunodetection was carried out with ME 101. Abbreviations are as in fig.2. 
brain and sympathetic ganglia, mouse neuro- 
blastoma NIE  115 cell line, rat sciatic nerve, rabbit 
sciatic nerve and spinal cord, chicken gizzard and 
sciatic nerve). From the results shown in fig.3, it is 
clear that ME 101 recognizes the amino-terminal 
moiety of  NF-L,  peripherin, vimentin, desmin and 
GFAP.  
4. D ISCUSSION 
ME 101 recognizes every IFP so far tested after 
transfer onto nitrocellulose membranes and it is 
clear f rom our results that the common epitope 
thus recognized is located on the amino-terminal 
half o f  the IFP. From the sequence data relative to 
these molecules [1-11], it can be inferred that ME 
101 recognizes the consensus equence located on 
coil la. Such an antibody may represent, as does 
the IFA  antibody, an interesting tool for detecting 
IFP  and their degradation products in cell extracts; 
it may be particularly useful in recognizing the rod 
domain or its amino-terminal half among the pro- 
ducts resulting from specific enzymatic or chemical 
degradations. However, since it has been 
demonstrated that the IFA antibody can also 
recognize the lamins [15], it would be of  interest o 
determine if it is also the case with ME 101. From 
the sequence data [16,17], it seems that lamins also 
possess the consensus equence located on coil la 
o f  the rod domain, demonstrating the highly con- 
served nature of  this port ion of  the molecule in the 
IFP.  
The IFA antibody has also been shown to ex- 
hibit a broad cross-species reactivity, since it 
recognizes IFP f rom many invertebrates [13,14]. It 
will be interesting to determine whether this would 
also be the case for ME 101 which would then con- 
stitute an additional marker for such studies; this 
would bring a supplementary element to the 
demonstrat ion of  the conservation of  the rod do- 
main during the phylogenetic evolution of  IFP. 
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